PARADIGM: Panitumumab + mFOLFOX6 vs Bevacizumab + mFOLFOX6 as First-line Treatment for mCRC With Wild-Type RAS

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
The phase III PARADIGM trial demonstrated superior overall survival with first-line panitumumab vs bevacizumab in combination with mFOLFOX6 in both the left-sided and overall mCRC populations with WT RAS.
Format: Microsoft PowerPoint (.ppt)
File Size: 217 KB
Released: June 9, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings